Effect of perioperative branched chain amino acids supplementation in liver cancer patients undergoing surgical intervention: A systematic review

Table 2 Baseline participant information of included randomised control trials, observational studies and non-randomised trials

Ref.	Country/year	Study design	Sample size			Gender (M/F)		Male (%)		Age (yr)		Pathology
			Intervention	Control	Total	Intervention	Control	Intervention	Control	Intervention	Control		Intervention	Control
Beppu et al[38]	Japan, 2015	RCT	13	15	28	9/4	10/5	69.2	66.7	64.7 (30.0)	68.4 (18.0)	Metastasis	1	2
												HCC	11	10
												Cholangiocarcinoma	1	3
												Others	0	0
Fan et al[43]	Hong Kong, 1994	RCT	64	60	124	56/9	53/7	87.5	88.3	51 (33.4)	53 (35)	Metastasis	0	0
												HCC	64	60
												Cholangiocarcinoma	0	0
												Others	0	0
Hachiya et al[39]	Japan, 2020	RCT	74	80	154	59/15	66/14	79.7	82.5	NR	NR	Metastasis	0	0
												HCC	74	80
												Cholangiocarcinoma	0	0
												Others	0	0
Ichikawa et al[40]	Japan, 2013	RCT	26	30	56	20/6	18/12	76.9	60	64.5 (11.4)	64.7 (9.8)	Metastasis	0	0
												HCC	26	30
												Cholangiocarcinoma	0	0
												Others	0	0
Ishikawa et al[30]	Japan, 2010	RCT	10	10	20	NR	NR	NR	NR	NR	NR	Metastasis	2	1
												HCC	7	7
												Cholangiocarcinoma	1	2
												Others1	1	3
Kikuchi et al[41]	Japan, 2016	RCT	39	38	77	31/8	29/9	79.5	76.3	69.4 (7.5)	71.9 (7.4)	Metastasis	0	0
												HCC	39	38
												Cholangiocarcinoma	0	0
												Others	0	0
Krapf et al[44]	Austria, 2021	RCT	12	9	21	NR	NR	NR	NR	NR	NR	Metastasis	NR	NR
												HCC	NR	NR
												Cholangiocarcinoma	NR	NR
												Others	NR	NR
Meng et al[31]	Hong Kong, 1999	RCT	21	23	44	19/2	18/5	90.5	78.3	51.5 (10.8)	53.3 (12.8)	Metastasis	0	0
												HCC	21	23
												Cholangiocarcinoma	0	0
												Others	0	0
Nagasue et al[32]	Japan, 1997	RCT	67	65	132	54/13	55/10	80.6	84.6	NR	NR	Metastasis	NR	NR
												HCC	NR	NR
												Cholangiocarcinoma	NR	NR
												Others	NR	NR
Okabayashi et al[33]	Japan, 2010	RCT	13	13	26	9/4	8/5	69.2	61.5	68.2 (11.0)	63.5 (5.7)	Metastasis	0	0
												HCC	8	7
												Adenocarcinoma	5	6
												Cholangiocarcinoma	0	0
												Others	0	0
Okabayashi et al[34]	Japan, 2011	RCT	40	36	76	29/11	24/12	72.5	66.7	68.7 (7.6)	65.1 (11.3)	Metastasis	0	0
												HCC	32	26
												Cholangiocarcinoma	8	10
												Others	0	0
Togo et al[42]	Japan, 2005	RCT	21	22	43	17/5	17/6	81	77.3	66.5 (4.5)	64.3 (9.1)	Metastasis	NR	NR
												HCC	NR	NR
												Cholangiocarcinoma	NR	NR
												Others	NR	NR
Ardito et al[45]	Japan, 2020	Retrospective	107	205	312	NR	NR	NA	NA	NR	NR	Metastasis	83	163
		Cohort										HCC	18	36
												Cholangiocarcinoma	6	6
												Others2	6	48
Okabayashi et al[35]	Japan, 2008	Retrospective	40	72	112	29/11	55/17	72.5	76.4	65.7 (8.6)	68.3 (8.1)	Metastasis	0	0
		Cohort										HCC	40	72
												Cholangiocarcinoma	0	0
												Others	0	0
Shirabe et al[37]	Japan, 2011	Retrospective	72	56	128	NR	NR	NR	NR	NR	NR	Metastasis	NR	NR
		Cohort										HCC	72	56
												Cholangiocarcinoma	NR	NR
												Others	NR	NR
Kobayashi et al[36]	Japan, 2019	Non- randomised trial	26	10	36	21/5	5/5	80.8	50	69.2 (29.0)	64.8 (26.7)	Metastasis	4	2
												HCC	22	8
												Cholangiocarcinoma	0	0
												Others	0	0

¹Benign.

²Benign, intra-hepatic stones, others.

RCT: Randomised controlled trial; HCC: Hepatocellular carcinoma; NR: Not reported.